Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Vaxil Bio Ltd V.VXL

Alternate Symbol(s):  VXLLF

Vaxil Bio Ltd. is a Canada-based biotechnology company. The Company is focused on a drug discovery and development platform based on Signal Peptides (SPs) which the Company deploys to fight infectious diseases and cancer. The Company’s most advanced product, ImMucin, a MUC1 SP-derived vaccine, completed a Phase I/II clinical trial in multiple myeloma. The Company also has a SP-based COVID-19 vaccine candidate and a SP-based tuberculosis vaccine / treatment candidate. In addition, The Company has mAb candidates for the treatment of oncology and infectious diseases to be used alone, and in combination with other treatments. It has also initiated a pre-clinical program for a drug delivery polymer that targets high affinity E-selectin (P-Esbp), which the Company licensed for development and commercialization from BGN Technologies. It exploits the properties of SP domains on crucial proteins to develop targeted therapies against cancer targets and infectious disease pathogens.


TSXV:VXL - Post by User

Post by silentrunningon Feb 23, 2021 4:43pm
274 Views
Post# 32639661

Could be good

Could be goodFrom what we're told....this may play out rather superbly "COVID-19 vaccines modified to work against circulating virus variants should have clinical immunogenicity studies supporting their effectiveness, and ensure they work not only against the variant strain, but the initial strain, the FDA said inmodified guidanceon Monday. Manufacturers will also need to conduct booster studies, where the modified vaccine is given to those already vaccinated with the initial vaccine, to measure immune response in those individuals as well." https://www.medpagetoday.com/infectiousdisease/covid19/91315?xid=nl_covidupdate_2021-02-23&eun=g1047875d0r&utm_source=Sailthru&utm_medium=email&utm_campaign=DailyUpdate_022321&utm_term=NL_Gen_Int_Daily_News_Update
<< Previous
Bullboard Posts
Next >>